PepsiCo Stock Slumps as Market Sees Value in Underrated Beverage Giant

The past five years have been a time of unprecedented growth for the stock market, with the S&P 500 index rising by around 70%. However, PepsiCo (PEP) has not fared as well, falling 12% during this period. The company's revenue is still substantial, nearing $100 billion annually, and its business is generating solid profits.

But what's going wrong for the beverage giant? One reason may be the impact of GLP-1 drugs on consumer appetite. These medications have been available for multiple years now, but PepsiCo's business hasn't collapsed as a result. In fact, its financials remain sound, suggesting that the market may be overreacting.

PepsiCo's stock is trading at an attractive valuation, with a price-to-earnings multiple of just 18, well below the S&P 500 average of 24 and Coca-Cola's multiple of 27. The company's growth may not be in double digits, but its fundamentals suggest it's more than fine.

For long-term investors, PepsiCo stock may prove to be an underrated buy right now, with solid numbers and attractive valuation potentially enabling it to outperform the market and its key rival from here on out.